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A B S T R A C T
Background: Acute kidney injury (AKI) frequently occurs following transcatheter aortic valve
implantation (TAVI) and has been related to a worse outcome. We investigated the importance of
contrast medium composition, either iso-osmolar (IOCM) or low-osmolar (LOCM) and assessed
predictors for AKI after TAVI.
Methods and results: We assessed AKI in 203 TAVI patients treated mainly with trans-femoral
implantation and analgosedation. A total of 100 patients received IOCM and 103 LOCM. AKI was deﬁned
according to the Valve Academic Research Consortium. Following TAVI, 39 patients (19.2%) developed
AKI; 17.0% of the IOCM and 21.4% of the LOCM group (p = 0.43). The only independent predictor for AKI
was baseline serum creatinine [odds ratio (OR) 0.26, 95% conﬁdence interval (CI) 0.01–0.64, p = 0.002].
Patients with advanced AKI (stages 2 and 3) post-TAVI had signiﬁcantly higher mortality at 2 years (log
rank p < 0.001), whereas patients with AKI stage 1 had a similar long-term outcome to non-AKI patients.
Conclusions: Following TAVI, we observed no difference in the occurrence of AKI between IOCM and
LOCM. Baseline creatinine was the only independent predictor of AKI, and patients who developed
advanced AKI had signiﬁcantly higher mortality at 2 years.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Transcatheter aortic valve implantation (TAVI) is a new
treatment modality for high-surgical-risk patients with severe
aortic stenosis, and is widely believed to carry lower peri-
procedural hazards than surgical valve replacement. It has been
reported that TAVI is an effective method to treat chronic renal
failure in, for example, kidney transplant recipients with severe
aortic stenosis and is associated with lower mortality compared to* Corresponding author at: Herzzentrum, Segeberger Kliniken GmbH, Am
Kurpark 1, 23795 Bad Segeberg, Germany. Tel.: +49 4551 802 4801;
fax: +49 4551 802 4805.
E-mail address: chatani.kenichi@gmail.com (K. Chatani).
http://dx.doi.org/10.1016/j.jjcc.2015.02.007
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightssurgical valve replacement [1]. TAVI, however, has distinct
requirements such as use of contrast injections and a relevant
risk of TAVI-induced acute kidney injury (AKI) [2]. Patients referred
for TAVI are usually elderly individuals who frequently have
preexisting renal impairment and other co-morbidities, which
aggravate the risk of AKI [3]. Recent studies have identiﬁed AKI
following TAVI as an independent predictor of late mortality [4],
but prediction and prevention of this complication remain
challenging. Controversy exists about the potential advantage of
iso-osmolar contrast media (IOCM) compared to low-osmolar
contrast media (LOCM) in patients treated with percutaneous
coronary interventions [5,6]. In this observational retrospective
study, we compared the incidence of AKI after TAVI in patients
receiving IOCM vs. LOCM. Additionally, we investigated predictors
for the occurrence of AKI following TAVI and assessed the reserved.
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long-term mortality. Finally we investigated predictors for 2-year
mortality following TAVI.
Methods
Patients and procedure
Between September 2007 and May 2012 a total of 212 patients
with severe symptomatic aortic stenosis were treated with TAVI at
our institution. Indications for TAVI were based on high morbidity
and mortality scores [>80 years of age and a logistic European
System for Cardiac Operative Risk Evaluation score (EuroSCORE)
>20% or a logistic EuroSCORE <20% in the presence of liver
cirrhosis, chronic pulmonary disease, or porcelain aorta] and after
discussing the patient’s data within the institutional heart team
[7–9]. Nine patients were excluded from the current analysis: ﬁve
patients were converted to surgery and four patients died within
3 days of the procedure. The remaining 203 patients comprised the
population of the current analysis. Full laboratory assessment
including serum creatinine level was performed before TAVI and
daily thereafter for 3 consecutive days. Additional analyses were
performed when clinically needed. Baseline transthoracic and
transesophageal echocardiography were performed in all patients
before TAVI, as were routine coronary angiography, right heart
catheterization, and peripheral angiography. Clinical events were
recorded for the in-hospital period, at 30 days, 6 months, 1 year,
and yearly thereafter. Patients who underwent TAVI from
September 2007 until May 2012 received the iso-osmolar contrast
medium iodixanol (Visipaque, GE Healthcare, Princeton, NJ, USA),
or the low-osmolar contrast medium iohexol (Accupaque, GE
Healthcare). A hydration strategy using intravenous normal saline
was adopted in all patients (starting 12 hs before TAVI and
continued during TAVI and for 12 h thereafter). We compared
patients that received IOCM with patients that received LOCM
regarding baseline clinical characteristics, echocardiographic and
angiographic data, the change in serum creatinine level post-TAVI,
and the occurrence of AKI. Furthermore, we assessed the predictive
factors for the occurrence of contrast-induced AKI, and examined
the relationship between the occurrence of contrast-induced AKI
and 2-year mortality after TAVI.
Deﬁnitions
AKI was deﬁned according to the Valve Academic Research
Consortium (VARC) consensus on event deﬁnition (modiﬁed RIFLE
classiﬁcation) as an absolute increase in serum creatinine (SCre)
>0.3 mg/dl or a percentage increase >50% within 72 h following
TAVI [10]. Patients who developed AKI were classiﬁed according to
the degree of severity in stage 1 (increase in SCre to 150–200% or
increase of >0.3 mg/dl), stage 2 (increase in SCre to 200–300%), or
stage 3 (increase in SCre >300% or increase of >4.0 mg/dl).
Advanced AKI was deﬁned as stage 2 and stage 3. Cardiovascular
mortality was deﬁned as any death from approximate cardiac
cause, non-witnessed death, death of unknown cause, or proce-
dure-related death.
Statistical analysis
Statistical analysis was performed with the JMP software
(Version 9.0, SAS Institute Inc., Cary, NC, USA). Continuous
variables are expressed as mean values  standard deviation and
were analyzed with the Student’s t-test. Discrete variables are
presented as counts and percentages and were analyzed by Pearson’s
chi-square test. Logistic regression analysis was used to determine
independent predictors of AKI and predictive factors associated with2-year mortality after TAVI. The variables entered into both models
were clinically relevant to the outcome and/or had a p-value <0.1 in
the univariate analysis. Kaplan–Meier survival plots were constructed
from the index procedure and up to 2 years thereafter and compared
using the log-rank test. The level of statistical signiﬁcance was set at
p < 0.05.
Results
Baseline clinical characteristics
The study cohort represented a typical TAVI population with a
mean age of 80 years, predominantly female patients, about one
quarter with diabetes mellitus, and a mean logistic EuroSCORE of
24.5%. The average mean gradient across the aortic valve was
47 mmHg, mean aortic valve area was 0.71 cm2, and left
ventricular (LV) function was slightly depressed (LV ejection
fraction 47.7  14.3%). Overall, 171 (84.2%) patients received the
Medtronic CoreValve prosthesis (Medtronic, Irvine, CA, USA) and 32
(15.8%) patients received the Edwards Sapien XT valve (Edwards
Lifesciences, Irvine, CA, USA). The vascular access was mainly trans-
femoral (199 patients) except for two patients treated through the
trans-subclavian route and two patients through the trans-apical
route. The mean amount of contrast used was 278.6  82.2 ml.
Further clinical characteristics are shown in Table 1 and echocardio-
graphic and angiographic characteristics are also shown in Table 1.
Comparison between IOCM and LOCM
As shown in Table 1 baseline clinical, echocardiographic, and
angiographic characteristics were comparable between patients
receiving IOCM and those receiving LOCM during TAVI, except that
hyperlipidemia was more prevalent in the IOCM group (73.0% vs.
50.5%, p = 0.0009). Due to ongoing institutional development in the
valve implantation strategy and the complete switch of contrast
media that was exclusively used in the ﬁrst or second part of the
observation period, the Edwards Sapien XT valve was only used in
the LOCM group and residual aortic regurgitation was higher in the
IOCM group (33% vs. 8.7%, p < 0.0001). However, factors with a
potential impact on renal function were well balanced. In
particular, diabetes mellitus was prevalent in 26.0% vs. 27.2%
(p = 0.85), baseline serum creatinine was 1.16  0.61 mg/dl vs.
1.12  0.45 mg/dl (p = 0.58), and the amount of contrast used was
287.9  80.3 ml vs. 269.2  83.4 ml (p = 0.12) in the IOCM and LOCM
groups, respectively.
The change in serum creatinine levels after TAVI is shown in
Fig. 1. There was no signiﬁcant difference between patients
receiving IOCM and those receiving LOCM in the average serum
creatinine level at each day until day seven post-TAVI. Seventeen
patients (17.0%) of the IOCM group and 22 patients (21.4%) of the
LOCM group had an AKI (any stage) after TAVI (p = 0.43). Advanced
AKI occurred in ﬁve patients (5.0%) of the IOCM group and six
patients (5.8%) of the LOCM group (p = 0.80, Fig. 2).
Factors associated with post-TAVI AKI
Baseline clinical, echocardiographic, and angiographic char-
acteristics stratiﬁed by the occurrence of post-TAVI AKI are shown
in Table 2. There were no signiﬁcant differences between patients
with and without AKI in most baseline clinical characteristics, but
baseline serum creatinine was higher (1.46  0.85 mg/dl vs.
1.05  0.38 mg/dl, p < 0.0001) and mean trans-valvular pressure
gradient was lower in the AKI group (47.8  15.8 mmHg vs.
41.6  16.7 mmHg, p = 0.04). The use of the Edwards Sapien XT
valve and the incidence of residual aortic regurgitation were not
different between either group. Multivariate logistic regression
Table 1
Baseline characteristics of the whole study population and stratiﬁed by the type of contrast medium.
All (n = 203) LOCM group (n = 103) IOCM group (n = 100) p-Value*
Clinical characteristics
Age (years) 79.9  6.7 79.7  7.1 80.0  6.7 0.80
Male gender, n (%) 88 (43.4) 39 (37.9) 49 (49.0) 0.11
Height (cm) 167.7  8.4 167.0  8.2 168.5  8.5 0.23
Weight (kg) 76.0  16.1 75.6  18.6 76.5  13.0 0.70
BMI (kg/m2) 27.0  5.4 27.0  6.3 27.0  4.5 0.94
BSA (m2) 1.85  0.20 1.83  0.22 1.86  0.18 0.39
Diabetes mellitus, n (%) 54 (26.6) 28 (27.2) 26 (26.0) 0.85
Hyperlipidemia, n (%) 125 (61.6) 52 (50.5) 73 (73.0) 0.0009
Hypertension, n (%) 173 (85.2) 89 (86.4) 84 (84.0) 0.63
Coronary artery disease, n (%) 152 (74.9) 75 (72.8) 77 (77.0) 0.49
PVD, n (%) 32 (15.8) 13 (12.6) 19 (19.0) 0.21
Previous stroke, n (%) 26 (12.8) 1 (0.9) 2 (2.5) 0.35
Hemoglobin (g/dl) 12.1  1.7 12.2  1.6 12.0  1.7 0.34
Baseline s. creatinine (mg/dl) 1.14  0.54 1.12  0.45 1.16  0.61 0.58
NYHA (III/IV), n (%) 187 (92.1) 92 (89.3) 95 (95) 0.13
Logistic EuroSCORE (%) 24.5  15.0 26.5  17.2 22.4  12.1 0.05
Echocardiography
EF (%) 47.7  14.3 46.9  14.0 48.5  14.5 0.42
AVA (cm2) 0.71  0.25 0.74  0.29 0.68  0.19 0.08
Mean PG (mmHg) 46.6  16.1 43.4  16.6 50.0  14.9 0.05
Peak PG (mmHg) 74.7  24.8 70.6  27.2 78.6  21.6 0.03
Diameter of aortic annulus (mm) 23.3  2.4 23.4  2.5 23.1  2.3 0.35
Diameter of ascending aorta (mm) 30.1  4.6 30.0  5.1 30.3  4.0 0.58
Angiography
Amount of contrast (ml) 278.6  82.2 269.2  83.4 287.9  80.3 0.12
Size of implanted valve (mm) 27.6  1.8 27.4  2.0 27.8  1.5 0.06
Signiﬁcant AR after TAVI (>grade 1), n (%) 42 (20.7%) 9 (8.7%) 33 (33%) <0.0001
Edwards Sapien XT valve 32 (15.8%) 32 (31.1%) 0 (0%) <0.0001
IOCM, iso-osmolar contrast media; LOCM, low-osmolar contrast media; BMI, body mass index; BSA, body surface area; PVD, peripheral vascular disease; NYHA, New York
Heart Association; EF, ejection fraction; AVA, aortic valve area; PG, pressure gradient; AR, aortic regurgitation; TAVI, transcatheter aortic valve implantation.
* p-Value for the comparison LOCM vs. IOCM.
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independent predictor for the occurrence of AKI post-TAVI (Table 3).
AKI and mortality
Clinical follow-up was 100% at 30 days and 98% at 1 year, with a
total mean observation period of 665  184 days. Overall, 30-day
mortality was 2.0% (4 patients). Cumulative mortality was 8.6%
(15 patients) at 6 months, 15.5% (20 patients) at 1 year, and 30.2%
(29 patients) at 2 years. Of the latter, 7 patients died due to a cardiac
cause and 22 patients died due to a non-cardiac cause.Fig. 1. Post-TAVI changes in serum creatinine level in patients receiving IOCM and
LOCM. TAVI, transcatheter aortic valve implantation; IOCM, iso-osmolar contrast
media; LOCM, low-osmolar contrast media.Kaplan–Meier survival curves for patients with and without AKI
showed a signiﬁcantly lower survival rate up to 2 years in the
overall AKI group (log rank p = 0.02, Fig. 3). As shown in Fig. 4,
survival rates were similar in patients with no AKI and those with
stage 1 AKI (log rank p = 0.37), but survival was signiﬁcantly worse
in patients with advanced AKI (stages 2 and 3, log rank p < 0.001).
Factors associated with mortality at 2 years in the multivariate
logistic regression analysis are shown in Table 4. The occurrence of
advanced AKI following TAVI and stroke following TAVI and male
sex remained predictors of 2-year mortality after TAVI (Table 4).Fig. 2. The occurrence of AKI following TAVI stratiﬁed by the type of contrast
medium. AKI, acute kidney injury; TAVI, transcatheter aortic valve implantation;
IOCM, iso-osmolar contrast media; LOCM, low-osmolar contrast media.
Table 2
Baseline characteristics in patients with and without post-TAVI AKI.
AKI group
(n = 39)
No AKI group
(n = 164)
p-Value*
Clinical characteristics
Age (years) 80.3  7.5 79.8  6.8 0.64
Male gender, n (%) 22 (56.4) 66 (40.2) 0.07
Height (cm) 168.6  9.5 167.5  8.1 0.47
Weight (kg) 75.0  15.8 80.1  16.9 0.08
BMI (kg/m2) 28.3  6.4 26.7  5.1 0.10
BSA (m2) 1.90  0.20 1.84  0.20 0.10
Diabetes mellitus, n (%) 10 (25.6) 44 (26.8) 0.88
Hyperlipidemia, n (%) 22 (56.4) 103 (62.8) 0.46
Hypertension, n (%) 31 (79.5) 142 (86.6) 0.28
Coronary artery disease, n (%) 31 (79.5) 122 (73.8) 0.43
Previous myocardial infarction,
n (%)
9 (23.1) 38 (23.2) 0.99
PVD, n (%) 7 (18.0) 25 (15.2) 0.68
Previous stroke, n (%) 5 (12.8) 21 (12.8) 0.99
Hemoglobin (g/dl) 12.2  1.7 12.1  1.7 0.88
Baseline s. creatinine (mg/dl) 1.46  0.85 1.05  0.38 <0.0001
NYHA (III/IV), n (%) 36 (92.3) 151 (92.1) 0.88
Logistic EuroSCORE (%) 28.8  20.2 23.5  13.4 0.05
Echocardiography
EF (%) 45.7  15.0 48.2  14.1 0.35
AVA (cm2) 0.72  0.21 0.71  0.26 0.85
Mean PG (mmHg) 41.6  16.7 47.8  15.8 0.04
Peak PG (mmHg) 67.7  28.0 76.4  23.7 0.06
Systolic pulmonary pressure
(mmHg)
46.9  14.9 44.4  15.6 0.40
Diameter of aortic
annulus (mm)
23.1  2.2 23.3  2.4 0.51
Diameter of ascending
aorta (mm)
30.1  4.1 30.2  4.8 0.99
Angiography
Amount of contrast (ml) 289.2  90.8 276.0  80.0 0.39
Size of valve (mm) 27.5  1.8 28.0  1.7 0.11
RBC transfusion, n (%) 10 (25.6) 37 (22.6) 0.68
Signiﬁcant AR after TAVI
(>grade 1), n (%)
10 (25.6) 32 (19.5) 0.41
Edwards Sapien XT valve, n (%) 6 (15.4) 26 (15.9) 0.94
AKI, acute kidney injury; BMI, body mass index; BSA, body surface area; PVD,
peripheral vascular disease; NYHA, New York Heart Association; EF, ejection
fraction; AVA, aortic valve area; PG, pressure gradient; RBC, red blood cell; AR,
aortic regurgitation; TAVI, transcatheter aortic valve implantation.
* p-Value for the comparison AKI group vs. No AKI group.
Fig. 3. Kaplan–Meier curves for overall survival in the AKI and non AKI group. AKI,
acute kidney injury.
Fig. 4. Kaplan–Meier curves for overall survival according to the grade of AKI. AKI,
acute kidney injury.
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Contrast osmolarity and the risk of post-TAVI AKI
Previous studies have suggested that IOCM are less nephrotoxic
than LOCM in patients undergoing angiography [11]. The osmo-
larity of LOCM is about 600–900 mOsm/L while that of IOCM is
about 300 mOsm/L, which is the same as physiologic osmolarity
[12]. Aspelin et al. [13] documented in a prospective, multicenter,
randomized double-blind trial that the incidence of contrast-
induced nephropathy after angiography was signiﬁcantly lower inTable 3
Results of multivariate logistic regression analysis for predictors of post-TAVI AKI.
Odds ratio 95% CI p-Value
RBC transfusion 0.65 0.25–1.78 0.39
Logistic EuroSCORE (%) 0.99 0.96–1.01 0.33
Type of contrast 1.35 0.55–3.39 0.51
Amount of contrast 1.00 1.003–1.001 0.50
Baseline creatinine value 0.26 0.01–0.64 0.002
Sex (male) 0.94 0.38–2.39 0.90
Weight 0.98 1.01–1.02 0.22
Mean aortic pressure gradient 1.02 0.99–1.05 0.29
TAVI, transcatheter aortic valve implantation; CI, conﬁdence interval; AKI, acute
kidney injury; RBC, red blood cell.patients receiving the IOCM iodixanol compared with the LOCM
iohexol. Hyperosmolarity of contrast media may play a role in the
pathogenesis of contrast-induced AKI by causing relatively greater
degrees of intra-renal vasoconstriction, activating tubuloglomer-
ular feedback, or increasing tubular hydrostatic pressure, all of
which could result in decreased glomerular ﬁltration rate and
worsening medullary hypoxemia [14–16]. However, on the otherTable 4
Results of multivariate logistic regression analysis for independent predictors of 2-
year mortality following TAVI.
Odds ratio 95% CI p-Value
Sex (male) 0.35 0.13–0.92 0.03
Baseline creatinine value 0.79 0.38–1.70 0.52
Logistic EuroScore 0.98 0.95–1.02 0.33
Left ventricular ejection fraction 1.00 0.97–1.04 0.83
Stroke following TAVI 0.10 0.02–0.48 0.004
Advanced AKI following TAVI 0.17 0.04–0.71 0.02
TAVI, transcatheter aortic valve implantation; CI, conﬁdence interval; AKI, acute
kidney injury.
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[5,17,18]. In a metaanalysis of 2763 patients included in
16 randomized trials, Reed et al. [5] found no difference between
iodixanol and LOCM overall in the occurrence of contrast-induced
AKI. In the present study, the ﬁrst to look at the effect of contrast
osmolarity in a TAVI cohort, there was also no difference in the
occurrence of AKI after TAVI between the IOCM iodixanol and the
LOCM iohexol. Iodixanol, a dimeric iso-osmotic contrast medium,
is more viscous than the monomeric low-osmotic iohexol [12]. The
increased viscosity may lead to extended retention periods within
the tubular system and an increase in direct toxic effects on tubular
cells [19]. Therefore, the risk of contrast-induced AKI probably
cannot be explained by osmolarity alone. Viscosity or whether the
contrast medium is dimeric or monomeric also has a signiﬁcant
impact on the risk of developing contrast-induced AKI [20]. In
addition, the type of contrast medium appears to be of minor
importance in the current TAVI population.
Predictive factors for the occurrence of AKI following TAVI
Mehran et al. [21] showed that the most important risk factors
for contrast-induced nephropathy after percutaneous coronary
intervention (PCI) are hypotension, intra-aortic balloon pump use,
congestive heart failure, serum creatinine >1.5 mg/dl, age >75
years, anemia, diabetes mellitus, and contrast volume. On the other
hand, recent studies have looked at predictors of contrast-induced
AKI following TAVI [4,22–24]. In the largest published series, Nuis
et al. [25] reported the number of units of blood transfusion 24 h
post-TAVI, peripheral vascular disease, history of heart failure,
leukocyte count 72 h after TAVI, and the logistic EuroSCORE as
independent predictors for the occurrence of AKI following TAVI. In
the current analysis, only baseline serum creatinine level before
TAVI was independently associated with post-TAVI AKI, a ﬁnding
that has also been recently reported by Elhmidi et al. in a series of
234 patients [23]. It thus appears that post-TAVI AKI may have a
different underlying pathophysiology. Neither the amount nor the
type of contrast medium appears to affect the occurrence of AKI,
and other accepted risk factors for AKI such as diabetes and
hypertension are of minor importance.
Contrast agents reduce the oxygen tension in the renal medulla
and renal ischemia occurs [12]. Rudnick et al. reported that renal
ischemia caused contrast-induced AKI [12]. In some studies it has
been shown that preexisting kidney disease is the greatest
predictive factor for the occurrence of AKI, which might be due
to decreased vasodilator response and aggravation of the renal
ischemia [26]. Some studies reported the severity of the
preexisting kidney disease (measured by serum creatinine level)
directly correlates with the occurrence of contrast-induced AKI
[15]. In this study, baseline creatinine was the only independent
predictor of AKI.
Predictive factors for 2-year mortality
Nombela-Franco et al. [27] reported the occurrence of major
stroke was associated with increased early and late mortality. In
this study also, stroke following TAVI was a predictor of 2-year
mortality. Hayashida et al. [28] showed that female sex was
associated with a signiﬁcantly lower mortality rate. In our study,
male sex was one of the predictive factors for 2-year mortality.
Female sex is a risk factor for major vascular complications. In this
study also, female sex was observed to be associated with a
signiﬁcantly higher incidence of major vascular complications
(8.7% vs. 0%, p = 0.006). Amabile et al. [29] reported that major
vascular complications were not the major causes of deaths after
TAVI. It is possible that the sex differences in the pathophysiologi-
cal characteristics serve as a possible underlying mechanism.Several papers have demonstrated cardiac remodeling and ﬁbrosis
to be less prevalent and less severe in women with aortic stenosis
than those in men with aortic stenosis or female sex is a protective
factor for atherosclerosis [30]. It is possible that this is one of the
reasons why male sex is associated with a higher mortality. Nuis
et al. [4] reported AKI following TAVI as a predictor of 30-day and
long-term mortality, and this has been consistently reported in other
series [22,25,31]. We also observed that long-term mortality up to
2 years after TAVI was signiﬁcantly higher in patients with post-TAVI
AKI. But importantly, this worse prognosis was conﬁned to patients
with advanced AKI (stages 2 and 3), while patients with stage 1 AKI
had similar mortality to patients with no AKI. Conversely, even
minor elevations of serum creatinine after PCI are associated with
impaired long-term outcome [32,33], which inﬂuenced the RIFLE
AKI deﬁnition. It is obvious from our observation that the translation
of the modiﬁed RIFLE deﬁnition for AKI from the PCI to the TAVI
population may lead to an overestimation of the clinical burden
associated with AKI following TAVI. This aspect has not been
addressed by the VARC group in the recently reported updated post-
TAVI endpoint deﬁnition, where the deﬁnition of AKI has only been
slightly modiﬁed [34]. Whether the strong relationship between
post-TAVI advanced AKI and mortality is causal (unlikely as AKI is
usually reversible) or a mere association (AKI as a marker of a sicker
patient population) remains to be determined.
Study limitations
The study has all the limitations of a single center registry and is
therefore subject to possible bias and confounding. Although all
parameters were prospectively collected into a dedicated institu-
tional TAVI database, the analyses were performed retrospectively,
and the deﬁnition of AKI was adopted after the initiation of data
collection. The small size of the study means that differences in the
occurrence of AKI according to the type of contrast medium used
may not have reached statistical signiﬁcance due to limited power,
but there was no clear trend toward a reduced incidence with
IOCM.
Conclusions
In this cohort of elderly high-risk patients treated with TAVI
with a standardized peri-procedural hydration protocol, the
incidence of AKI was 19.2% and the incidence of advanced AKI
was 5.4%. There was no signiﬁcant difference in the occurrence of
AKI between patients receiving the IOCM iodixanol and those
receiving the LOCM iohexol. Only baseline serum creatinine was
independently associated with post-TAVI AKI. The occurrence of
stroke following TAVI and male sex and the occurrence of advanced
AKI following TAVI were predictors of mortality at 2 years.
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